Preview Research free. Sign in to unlock 3 full asset or company pages every day, no card needed.Sign in to unlock this page

Company profile

Roche

Diversified pharma

RHHBY · OTC · Switzerland

Share price · RHHBY

$55.53+4.43 (+8.67%) 3M

close as of 2026-08-18 · 24h delayed · vol 125K

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Research

See what was announced around each unusual move

Research flags the days this stock moved far more than its sector fund, lists the news, filings and earnings dated around each one, and shows how much of its unusual movement fell on each asset's announcements.

Assets

(49 total)
49Total Assets
21Approved
14Phase 3 / Filed
14Phase 1–2 / Early
22Diseases
Quick filter:
Showing 49 of 49 assets
Target & Modality
Alectinib(Alecensa)
Approved
ALKSmall molecule
Non-Small Cell Lung Cancer
Approved
PD-L1Monoclonal antibody
Non-Small Cell Lung Cancer
Approved
VEGF-A · Vascular Endothelial Growth Factor InhibitorMonoclonal antibody
Non-Small Cell Lung Cancer
Approved
Multi-kinase inhibitor (VEGFR/PDGFR/KIT)Small molecule
Non-Small Cell Lung CancerRenal Cell CarcinomaHepatocellular Carcinoma
Clear Cell Renal Cell Carcinoma
Approved
GABA-A receptorSmall molecule
Epilepsy
Approved
ROS1/NTRKSmall molecule
Non-Small Cell Lung Cancer
Approved
Angiopoietin-2 / VEGF-AMultispecific antibody
Age-Related Macular Degeneration
Approved
PI3K-alphaSmall molecule
Breast Cancer
HR+/HER2- Metastatic Breast Cancer
Approved
CD20Monoclonal antibody
Multiple Sclerosis
Approved
CD20Monoclonal antibody
Multiple Sclerosis
Omalizumab(Xolair)
Approved
IgE (immunoglobulin E) · IgEMonoclonal antibody
Asthma
orlistat(Xenical / Alli)
Approved
Pancreatic/gastric lipaseSmall molecule
Obesity
Approved
Type I interferon receptor
Chronic Hepatitis B
Approved
PyridoneSmall molecule
Idiopathic Pulmonary Fibrosis
Approved
RETSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

Research

Unlock the company readout calendar

Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.

Financial reports

Unlock with Research ↗
Research

Unlock sourced financial history

Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.

Insider transactions

Unlock with Research ↗
Research

Unlock insider transactions

Research includes SEC Form 4 insider transactions: filed buys, sells, awards and exercises linked to the underlying filings.

Institutional holders

Unlock with Research ↗
Research

Unlock institutional holders

Research includes quarterly SEC 13F institutional ownership: top holders, aggregate positions and quarter-over-quarter context.